세계 통풍 시장 규모는 조사 기간 동안 복합 연간 성장률(CAGR) 11.75%를 나타낼 것으로 예측되고 있습니다. 생활양식의 변화나 노년인구의 확대에 의한 통풍의 유행이 기간중 시장 성장을 뒷받침할 전망입니다.
지역 고찰
북미 시장 규모는 2022년에 18억 달러가 되어 조사 기간에 복합 연간 성장률(CAGR)로 12.03%의 성장을 보여줄 전망입니다. 미국 시장이 가장 큰 시장 점유율을 차지하고 있는데, 이는 통풍 우위 증가와 바이오 의약품의 수용 확대, 재생 의료에 관한 연구 개발 증가에 기인합니다.
유럽 시장이 2위 시장 점유율을 차지할 전망입니다. 아시아태평양 시장은 2023년부터 2030년에 복합 연간 성장률(CAGR) 13.12%를 나타낼 전망입니다.
이 보고서는 세계 통풍 시장에 대한 조사 분석, 시장 역학, 지역 및 부문 분석, 기업 프로파일 등을 제공합니다.
목차
제1장 주요 요약
제2장 시장의 소개
제3장 조사 방법
제4장 시장 역학
개요
성장 촉진요인
통풍의 유행
의료 지출 증가
연구개발 활동 증가
억제요인
통풍치료제의 부작용
사람들의 인식 부족
기회
전략적 노력 증가
제5장 시장 요인 분석
밸류체인 분석
연구개발
제조
유통 및 판매
판매 후 모니터링
Porter's Five Forces 분석 모델
세계 통풍 시장에 대한 COVID-19의 영향
밸류체인에 미치는 영향
공급망에 미치는 영향
주요 기업에 미치는 영향
제6장 세계 통풍 시장 : 진단 및 치료별
개요
진단
치료
NSAIDs
코르티코스테로이드
콜히친
요산강하제
기타
제7장 세계 통풍 시장 : 용도별
개요
급성 통풍
만성 통풍
제8장 세계 통풍 시장 : 최종 사용자별
개요
병원 및 진료소
전문센터
기타
제9장 세계 통풍시장 : 지역별
개요
북미
미국
캐나다
유럽
독일
영국
프랑스
이탈리아
스페인
기타 유럽
아시아태평양
중국
일본
인도
호주
한국
기타 아시아태평양
기타 지역
중동
아프리카
라틴아메리카
제10장 경쟁 구도
개요
경쟁 벤치마킹
세계 통풍시장의 주요 성장 전략
세계 통풍시장에서 개발수의 주요 기업
주요 개발 분석
주요 발전과 성장 전략
제품 출시 및 제품 승인
파트너십 및 합의
재무 매트릭스
매출(2022년)
연구개발 지출(2022년)
제11장 기업 프로파일
NOVARTIS AG
LANNETT
HORIZON THERAPEUTICS PLC
TAKEDA PHARMACEUTICAL COMPANY LIMITED
GLAXOSMITHKLINE PLC
REGENERON PHARMACEUTICALS, INC.
TEIJIN LIMITED
VIATRIS INC.
BOEHRINGER INGELHEIM INTERNATIONAL GMBH.
ROMEG THERAPEUTICS, LLC
제12장 부록
BJH
영문 목차
영문목차
Market Overview
Gout Market is anticipated to register a significant CAGR of 11.75% during the review period.
Gout is a kind of provocative joint pain that influences men beyond 40 a year old, have a high measure of uric corrosive in their blood. As per studies, its commonness and frequency have expanded over the most recent couple of many years. The rising commonness of gout because of changing way of life designs and the developing geriatric populace is supposed to help market development over the gauge period. For example, according to the article distributed by the Records of Rheumatic Sicknesses in June 2021, a cross country companion concentrates on utilizing information from the Clinical Practice Research Datalink, from 1997 to across the Coronavirus pandemic in 2021 saw that the predominance pace of gout has expanded from 0.98%in 1997 to 2.33% in 2021. Notwithstanding, as per a similar source, the frequency of gout expanded by 0.98/1,000 people in UK 2021. Thusly, the weight of gout is supposed to build the interest in drugs treating this condition, which is expected to impel the market development over the estimate period.
Market Segmentation
The Gout Market segmentation, based on treatment and diagnosis, includes diagnosis, treatment. The treatment segment is further sub segmented into NSAIDs, corticosteroids, colchicine, urate-lowering agents, and others.
The Gout Market segmentation is based on applications that include acute gout and chronic gout. The Gout Market segmentation is based on hospitals & clinics, specialty centers, and others.
Regional Insights
The North America region fragmented into US, and Canada. The North America region held the biggest market share in the Gout Endlessly market is represented USD 1.80 billion of every 2022 and is supposed to display a 12.03% CAGR during the review time frame. Further, in the North America region the US gout market represented the biggest market share. This is credited to the rising predominance of gout, developing reception of biologics, and rising Research and development exercises on regenerative prescriptions.
Europe gout market is supposed to represent the second-biggest market share because of the availability to cutting edge finding and treatment offices, the rising geriatric populace inclined to gout is driving up interest for powerful treatment and therapeutics and developing medical care consumption. The Asia-Pacific gout market is supposed to develop at a CAGR of 13.12% from 2023 to 2030. This is because of variables like further developing medical care framework, developing speculation by central parts with neighbourhood producers, and the rising patient populace experiencing gout.
The Rest of the World incorporates the Middle East, Africa, and Latin America. Middle East hold the significant market share in middle east and Africa region because of restricted medical care framework, a shortage of mindfulness regarding the side effects of the sickness, and an absence of talented experts to make gout therapeutics drugs are restricting the development of the gout market in Sub-Saharan Africa.
Major Players
Key Companies in the Gout Market are Novartis AG (Switzerland), Lannett (US), Horizon Therapeutics plc (US), Takeda Pharmaceutical Company Limited (Japan), GlaxoSmithKline plc (UK), Regeneron Pharmaceuticals, Inc (US), Teijin Limited (Japan), Viatris Inc (US), Boehringer Ingelheim International GmbH (Germany), and ROMEG Therapeutics, LLC (US).
TABLE OF CONTENTS
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY 13
1.1 OVERVIEW 13
2 MARKET INTRODUCTION 14
2.1 DEFINITION 14
2.2 SCOPE OF THE STUDY 14
2.3 RESEARCH OBJECTIVE 14
2.4 MARKET STRUCTURE 15
2.5 ASSUMPTIONS & LIMITATIONS 15
3 RESEARCH METHODOLOGY 16
3.1 DATA MINING 16
3.2 SECONDARY RESEARCH 17
3.3 PRIMARY RESEARCH 18
3.4 BREAKDOWN OF PRIMARY RESPONDENTS 19
3.5 FORECASTING TECHNIQUES 20
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 21
3.6.1 BOTTOM-UP APPROACH 22
3.6.2 TOP-DOWN APPROACH 22
3.7 DATA TRIANGULATION 23
3.8 VALIDATION 23
4 MARKET DYNAMICS 24
4.1 OVERVIEW 24
4.2 DRIVERS 25
4.2.1 INCREASING PREVALENCE OF GOUT 25
4.2.2 RISING HEALTHCARE EXPENDITURE 25
4.2.3 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES 26
4.3 RESTRAINTS 27
4.3.1 SIDE EFFECTS OF GOUT THERAPEUTIC DRUGS 27
4.3.2 LACK OF AWARENESS AMONG PEOPLE 28
4.4 OPPORTUNITY 28
4.4.1 RISING NUMBER OF STRATEGIC INITIATIVES 28
5 MARKET FACTOR ANALYSIS 29
5.1 VALUE CHAIN ANALYSIS 29
5.1.1 R&D 30
5.1.2 MANUFACTURING 30
5.1.3 DISTRIBUTION & SALES 30
5.1.4 POST-SALES MONITORING 30
5.2 PORTER'S FIVE FORCES MODEL 31
5.2.1 THREAT OF NEW ENTRANTS 31
5.2.2 BARGAINING POWER OF SUPPLIERS 32
5.2.3 THREAT OF SUBSTITUTES 32
5.2.4 BARGAINING POWER OF BUYERS 32
5.2.5 INTENSITY OF RIVALRY 32
5.3 IMPACT OF COVID-19 ON THE GLOBAL GOUT MARKET 33
5.3.1 IMPACT ON VALUE CHAIN 33
5.3.2 IMPACT ON SUPPLY CHAIN 33
5.3.3 IMPACT ON KEY PLAYERS 33
6 GLOBAL GOUT MARKET, BY DIAGNOSIS & TREATMENT 34
6.1 OVERVIEW 34
6.2 DIAGNOSIS 36
6.3 TREATMENT 36
6.3.1 NSAIDS 37
6.3.2 CORTICOSTEROIDS 37
6.3.3 COLCHICINE 38
6.3.4 URATE-LOWERING AGENTS 38
6.3.5 OTHERS 39
7 GLOBAL GOUT MARKET, BY APPLICATION 40
7.1 OVERVIEW 40
7.2 ACUTE GOUT 41
7.3 CHRONIC GOUT 42
8 GLOBAL GOUT MARKET, BY END USER 43
8.1 OVERVIEW 43
8.2 HOSPITALS & CLINICS 44
8.3 SPECIALTY CENTERS 45
8.4 OTHERS 45
9 GLOBAL GOUT MARKET, BY REGION 46
9.1 OVERVIEW 46
9.2 NORTH AMERICA 48
9.2.1 US 50
9.2.2 CANADA 51
9.3 EUROPE 52
9.3.1 GERMANY 54
9.3.2 UK 55
9.3.3 FRANCE 56
9.3.4 ITALY 57
9.3.5 SPAIN 58
9.3.6 REST OF EUROPE 59
9.4 ASIA-PACIFIC 61
9.4.1 CHINA 63
9.4.2 JAPAN 64
9.4.3 INDIA 65
9.4.4 AUSTRALIA 66
9.4.5 SOUTH KOREA 67
9.4.6 REST OF ASIA PACIFIC 68
9.5 REST OF THE WORLD 69
9.5.1 MIDDLE EAST 71
9.5.2 AFRICA 72
9.5.3 LATIN AMERICA 73
10 COMPETITIVE LANDSCAPE 74
10.1 OVERVIEW 74
10.2 COMPETITIVE BENCHMARKING 75
10.3 MAJOR GROWTH STRATEGY IN THE GLOBAL GOUT MARKET 76
10.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL GOUT MARKET 77
10.5 KEY DEVELOPMENT ANALYSIS 77
10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 78
10.6.1 PRODUCT LAUNCH/ PRODUCT APPROVAL 78
10.6.2 PARTNERSHIPS/ AGREEMENTS 78
10.7 FINANCIAL MATRIX 78
10.7.1 SALES (USD MILLION), 2022 78
10.7.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION), 2022 79
11 COMPANY PROFILES 80
11.1 NOVARTIS AG 80
11.1.1 COMPANY OVERVIEW 80
11.1.2 FINANCIAL OVERVIEW 81
11.1.3 PRODUCTS OFFERED 81
11.1.4 KEY DEVELOPMENTS 81
11.1.5 SWOT ANALYSIS 82
11.1.6 KEY STRATEGIES 82
11.2 LANNETT 83
11.2.1 COMPANY OVERVIEW 83
11.2.2 FINANCIAL OVERVIEW 83
11.2.3 PRODUCTS OFFERED 84
11.2.4 KEY DEVELOPMENTS 84
11.2.5 KEY STRATEGIES 84
11.3 HORIZON THERAPEUTICS PLC 85
11.3.1 COMPANY OVERVIEW 85
11.3.2 FINANCIAL OVERVIEW 86
11.3.3 PRODUCTS OFFERED 86
11.3.4 KEY DEVELOPMENTS 86
11.3.5 KEY STRATEGIES 87
11.4 TAKEDA PHARMACEUTICAL COMPANY LIMITED 88
11.4.1 COMPANY OVERVIEW 88
11.4.2 FINANCIAL OVERVIEW 88
11.4.3 PRODUCTS OFFERED 89
11.4.4 KEY DEVELOPMENTS 89
11.4.5 KEY STRATEGIES 89
11.5 GLAXOSMITHKLINE PLC 90
11.5.1 COMPANY OVERVIEW 90
11.5.2 FINANCIAL OVERVIEW 91
11.5.3 PRODUCTS OFFERED 91
11.5.4 KEY DEVELOPMENTS 91
11.5.5 SWOT ANALYSIS 92
11.5.6 KEY STRATEGIES 92
11.6 REGENERON PHARMACEUTICALS, INC. 93
11.6.1 COMPANY OVERVIEW 93
11.6.2 FINANCIAL OVERVIEW 93
11.6.3 PRODUCTS OFFERED 94
11.6.4 KEY DEVELOPMENTS 94
11.6.5 KEY STRATEGIES 94
11.7 TEIJIN LIMITED 95
11.7.1 COMPANY OVERVIEW 95
11.7.2 FINANCIAL OVERVIEW 95
11.7.3 PRODUCTS OFFERED 96
11.7.4 KEY DEVELOPMENTS 96
11.7.5 SWOT ANALYSIS 96
11.7.6 KEY STRATEGIES 96
11.8 VIATRIS INC. 97
11.8.1 COMPANY OVERVIEWS 97
11.8.2 FINANCIAL OVERVIEW 98
11.8.3 PRODUCTS OFFERED 98
11.8.4 KEY DEVELOPMENTS 98
11.8.5 SWOT ANALYSIS 99
11.8.6 KEY STRATEGIES 99
11.9 BOEHRINGER INGELHEIM INTERNATIONAL GMBH. 100
11.9.1 COMPANY OVERVIEW 100
11.9.2 FINANCIAL OVERVIEW 101
11.9.3 PRODUCTS OFFERED 101
11.9.4 KEY DEVELOPMENTS 102
11.9.5 SWOT ANALYSIS 102
11.9.6 KEY STRATEGIES 102
11.10 ROMEG THERAPEUTICS, LLC 103
11.10.1 COMPANY OVERVIEW 103
11.10.2 FINANCIAL OVERVIEW 103
11.10.3 PRODUCTS OFFERED 103
11.10.4 KEY DEVELOPMENTS 103
11.10.5 KEY STRATEGIES 103
12 APPENDIX 104
12.1 REFERENCES 104
12.2 WORLD HEALTH ORGANIZATION 104
12.3 THE GOUT EDUCATION SOCIETY 104
12.4 ARTHRITIS FOUNDATION 104
12.5 AMERICAN ARTHRITIS SOCIETY 104
12.6 SOUTH AFRICAN RHEUMATISM AND ARTHRITIS ASSOCIATION (SARAA) 104
12.7 EMIRATES ARTHRITIS FOUNDATION 104
12.8 ARTHRITIS FOUNDATION OF ASIA 104
12.9 OSTEOARTHRITIS RESEARCH SOCIETY INTERNATIONAL (OARSI) 104
12.10 SOAR - SOCIETY FOR OSTEOARTHRITIS RESEARCH 104
12.11 THE EUROPEAN ALLIANCE OF ASSOCIATIONS FOR RHEUMATOLOGY 104
